|Systematic (IUPAC) name|
|Mol. mass||269.345 g/mol|
|Metabolism||by monoamine oxidase|
|Half life||2–3 hours|
|Excretion||82% urine; 12% faeces|
is this?) (verify)|
Rizatriptan (Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.
Rizatriptan is available only by prescription in the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv) and Israel (as Rizalt).
Rizatriptan is used to treat acute migraine attacks. It does not prevent future migraine attacks.
Ear, nose, and throat: